Recombinant PDCD1 (Spartalizumab Biosimilar) antibody
Reactivity: Human
FACS, BLI, ELISA, Func, SPR
Host: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all PDCD1 (Spartalizumab Biosimilar) products
- PDCD1 (Spartalizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Human
- Expression System
- CHO Cells
-
Clonality
- Monoclonal
-
Conjugate
- This PDCD1 (Spartalizumab Biosimilar) antibody is un-conjugated
- Application
- Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)
- Purpose
- Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab)
- Characteristics
- Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.56 kDa.
- Purity
- >95 %
- Isotype
- IgG4SP
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Concentration
- 1 mg/mL
- Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- Storage
- 4 °C,-80 °C
- Storage Comment
- +4°C,-80°C
-
- Target
- PDCD1 (Spartalizumab Biosimilar)
- Abstract
- PDCD1 (Spartalizumab Biosimilar) Products
- Target Type
- Biosimilar
- Molecular Weight
- 145.56 kDa
- UniProt
- Q15116
-
You are here:
